Fig. 4
From: Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro
TGF-β1 induced reduction in receptor expression occurs via an ALK5 related pathway. a) Representative western blots and densitometry (b) from BAEC exposed to control conditions (C; DMSO vehicle), 5 μM SB-431542 (an ALK5 inhibitor) in DMSO (SB), 5 ng/ml exogenous TGF-β1 (T) or 5.0 ng/ml TGF-β1 plus 5 μM SB-431542 (T + SB) for 24 h. TGF-β1 leads reduced VEGFR2 expression and activation, and significantly upregulated endoglin in an ALK5/SMAD2-dependent fashion (as revealed by pSMAD2). There were no significant changes in SMAD1/5-dependent signaling, or in VEGFR1, Notch1 or Dll4 expression. *p ≤ 0.05; N = 3; Kruskal-Wallis test